Experimental colitis decreases rat jejunal amino acid absorption: role of capsaicin sensitive primary afferents.
Ulcerative colitis and experimental colitis are known to be associated with functional and structural abnormalities of the small intestine. The aim of this study was to determine whether experimental colitis in the rat has any effect on jejunal amino acid absorption and to investigate the neural mechanisms involved. In Sprague Dawley rats, colitis was induced by intracolonic administration of 0.1 ml of 6% iodoacetamide. Alanine absorption in the jejunum was measured using the single pass intraluminal perfusion technique in vivo and the three-compartment model in vitro. Experiments were done in normal and sham treated rats, as well as in rats that underwent neonatal capsaicin treatment, adult capsaicin treatment, or subdiaphragmatic vagotomy. Colitis was more severe in rats subjected to neonatal or adult capsaicin treatment, but was not affected by subdiaphragmatic vagotomy. In rats with colitis, jejunal alanine absorption was reduced by 2% (P>0.05), 28%, 40%, and 18% (P<0.001) at 1, 1.5, 2, and 3 days post rectal iodoacetamide administration. A rebound increase of 12% above baseline was noted at 4 days (P<0.05). Similar results were noted in vitro. In rats that received two consecutive injections of iodoacetamide, the decrease in jejunal alanine absorption occurred earlier, was more severe, and persisted for more than 30 days. Neonatal as well as adult capsaicin treatment aggravated both the colitis and the decrease in jejunal alanine absorption. On the other hand, subdiaphragmatic vagotomy attenuated the decrease in jejunal alanine absorption, but had no significant effect on colitis severity. It is concluded that iodoacetamide induced colitis impairs jejunal amino acid absorption and that this effect involves vagal efferents as well as capsaicin sensitive primary afferents.
Barada
K A
KA
Department of Internal Medicine, American University of Beirut, Lebanon.
Kafrouni
M I
MI
Khoury
C I
CI
Saade
N E
NE
Mourad
F H
FH
Szabo
S S
SS
Nassar
C F
CF
D000344:Afferent Pathways / Q000187:drug effects; D000409:Alanine / Q000378:metabolism*; D000818:Animals; D000831:Animals, Newborn; D002211:Capsaicin / Q000008:administration & dosage / Q000494:pharmacology; D003092:Colitis / Q000139:chemically induced / Q000378:metabolism* / Q000473:pathology; D003714:Denervation; D004195:Disease Models, Animal; D005260:Female; D066298:In Vitro Techniques; D007279:Injections, Subcutaneous; D007408:Intestinal Absorption; D007413:Intestinal Mucosa / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D007460:Iodoacetamide / Q000633:toxicity; D007583:Jejunum / Q000187:drug effects / Q000294:innervation / Q000378:metabolism*; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors; D014628:Vagotomy; D014630:Vagus Nerve / Q000166:cytology / Q000187:drug effects
D000409:Alanine; D002211:Capsaicin; D007460:Iodoacetamide